Oct 10, 2022
Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer
Sept 28, 2022
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Back to News
